• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CBR1 Gene Record

  • Summary
  • Interactions
  • Claims
  • CBR1 873 Druggable Genome

    Alternate Names:

    873
    CARBONYL REDUCTASE 1
    CBR1
    CBR
    SDR21C1
    hCBR1
    114830
    1548
    ENSG00000159228
    OTTHUMG00000086618
    PA26121
    CARBONYL REDUCTASE [NADPH] 1 (EC 1.1.1.184) (NADPH-DEPENDENT CARBONYL REDUCTASE 1) (PROSTAGLANDIN-E(2) 9-REDUCTASE) (EC 1.1.1.189) (PROSTAGLANDIN 9-KETOREDUCTASE) (15-HYDROXYPROSTAGLANDIN DEHYDROGENASE [NADP+]) (EC 1.1.1.197). [SOURCE:UNIPROT/SWISSPROT;AC
    P16152
    CBR1_HUMAN
    CARBONYL REDUCTASE [NADPH] 1
    S-nitrosoglutathione reductase
    T70518
    PG-9-KR

    Gene Info:

    Human Readable Name DRUGGABLE GENOME
    Interpro Acc IPR002198
    Human Readable Name SHORT CHAIN DEHYDROGENASE REDUCTASE
    Interpro Short Name DH_sc/Rdtase_SDR
    Uniprot Status Swiss-Prot
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Family
    Interpro Name Short-chain dehydrogenase/reductase SDR
    Gene Biotype PROTEIN_CODING
    (2 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME
    SHORT CHAIN DEHYDROGENASE REDUCTASE

    Publications:

    Thorn CF et al., 2011, Doxorubicin pathways: pharmacodynamics and adverse effects., Pharmacogenet Genomics
    Bains OS et al., 2009, Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin., Drug Metab Dispos
    Gonzalez-Covarrubias V et al., 2009, Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors., Drug Metab Dispos
    Lal S et al., 2008, CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients., Cancer Sci
  • N6022   CBR1

    Interaction Score: 12.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • DOXORUBICIN   CBR1

    Interaction Score: 0.66

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21048526 19204081 19022938 19016765


    Sources:
    PharmGKB

  • DAUNORUBICIN   CBR1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19204081


    Sources:
    PharmGKB

  • CYCLOPHOSPHAMIDE   CBR1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   CBR1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000159228

    • Version: 101_38

    Alternate Names:
    CBR1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000159228

    • Version: 26-July-2011

    Alternate Names:
    CBR1 Display Id
    ENSG00000159228 Ensembl Gene Id
    CARBONYL REDUCTASE [NADPH] 1 (EC 1.1.1.184) (NADPH-DEPENDENT CARBONYL REDUCTASE 1) (PROSTAGLANDIN-E(2) 9-REDUCTASE) (EC 1.1.1.189) (PROSTAGLANDIN 9-KETOREDUCTASE) (15-HYDROXYPROSTAGLANDIN DEHYDROGENASE [NADP+]) (EC 1.1.1.197). [SOURCE:UNIPROT/SWISSPROT;AC Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P16152

    • Version: 11-September-2012

    Alternate Names:
    873 Entrez Gene Id
    P16152 Uniprot Accession
    ENSG00000159228 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME
    Human Readable Name SHORT CHAIN DEHYDROGENASE REDUCTASE
    Interpro Short Name DH_sc/Rdtase_SDR

    Gene Categories:
    DRUGGABLE GENOME, SHORT CHAIN DEHYDROGENASE REDUCTASE

    Publications:

  • PharmGKB: CBR1

    • Version: 18-August-2020

    Alternate Names:
    PA26121 PharmGKB ID

    Gene Info:

    Publications:
    Blanco JG et al., 2012, Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group., J Clin Oncol
    Lal S et al., 2008, CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients., Cancer Sci
    Bains OS et al., 2009, Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin., Drug Metab Dispos

  • HingoraniCasas: ENSG00000159228

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000159228 Gene Symbol
    CBR1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TTD: S-nitrosoglutathione reductase

    • Version: 2020.06.01

    Alternate Names:
    CBR1 TTD Gene Abbreviation
    T70518 TTD Target ID

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21